EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

Cinzia Dello Russo iD, Iain Frater iD, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S F Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves und 11 weitere

British Journal of Clinical Pharmacology · 2026-02 · 92 (2) · 329-347

DOI: 10.1002/bcp.70370 ↗

Kurz gefasst

Leitlinie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 03.12.2025. Verfasst von Cinzia Dello Russo und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Clopidogrel, Platelet Aggregation Inhibitors, Pharmacogenomic Testing. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovate UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective. CYP2C19 is encoded by a polymorphic gene; variants in the CYP2C19 gene, which vary in frequency in different ethnic groups can abolish, reduce or increase enzyme activity, thereby affecting the conversion of clopidogrel to its active metabolite. Individuals who have either one or two loss‐of‐function alleles are referred to as intermediate and poor metabolisers, respectively, and in these patients, the clinical effectiveness of clopidogrel is reduced or absent. Any patient about to be prescribed clopidogrel, regardless of the underlying indication, should have pharmacogenetic testing to identify clinically relevant CYP2C19 variants, where testing is available, to optimize their antiplatelet therapy. Clopidogrel use should be avoided in patients with an intermediate or poor CYP2C19 metaboliser phenotype in all approved indications and alternative treatment regimens used as detailed in this guideline. Our guideline is compatible with other international pharmacogenetic prescribing guidelines, but we also provide recommendations in other areas. Summary guidance on a page is provided for each of the indications in Boxes 1–3. This guideline is grounded in the latest evidence in this field but cannot account for all individual factors relevant to patient care. Therefore, prescribers must conduct a thorough assessment of each patient's risk–benefit profile, ensuring that therapy is optimized to maximize benefits while minimizing potential harms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C19ClopidogrelPlatelet Aggregation InhibitorsPharmacogenomic TestingHumansUnited KingdomGenotype

Stichwörter der Autor:innen

CYP2C19clopidogrelcoronary artery diseasehealth economicsperipheral arterial diseasepharmacogenetic testingstroke

Substanzen

Cytochrome P-450 CYP2C19ClopidogrelPlatelet Aggregation InhibitorsCYP2C19 protein, human

Autor:innen und Institutionen

  • Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Department of Healthcare Surveillance and Bioethics, Section of Pharmacology, Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
  • The Wolfson Centre for Personalised Medicine, Centre for Drug Safety Science, University of Liverpool, Liverpool, UK.
  • Queen Elizabeth University Hospital, Glasgow, UK.
  • East of Scotland Vascular Network, Department of Vascular Surgery, University of Dundee, Dundee, UK.

ORCID-Profile: Cinzia Dello Russo, Iain Frater, Dyfrig A Hughes, Munir Pirmohamed

Förderung

  • Innovate UK

Zitieren

APA

Dello Russo, C., Frater, I., Kuruvilla, R., Lip, S., O'Neill, H., Burke, K., Chaplin, V., Doney, A. S. F., Elyas, S., Greaves, N., Harding, S., Hargroves, D., Hayward, J., Hughes, D. A., Hughes, T. A. T., Kondapally, S., Mok, P., Peace, A., Rafi, I., …, & Pirmohamed, M. (2026). CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx). British Journal of Clinical Pharmacology, 92(2), 329-347. https://doi.org/10.1002/bcp.70370

Vancouver

Dello Russo C, Frater I, Kuruvilla R, Lip S, O'Neill H, Burke K, et al. CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx). British Journal of Clinical Pharmacology. 2026;92(2):329-347. doi:10.1002/bcp.70370

BibTeX
@article{DelloRusso2026,
  author = {Dello Russo, Cinzia and Frater, Iain and Kuruvilla, Rebecca and Lip, Stefanie and O'Neill, Hannah and Burke, Kerry and Chaplin, Vicky and Doney, Alexander S F and Elyas, Salim and Greaves, Nicholas and Harding, Sophie and Hargroves, David and Hayward, Judith and Hughes, Dyfrig A and Hughes, Tom A T and Kondapally, Sree and Mok, Patrick and Peace, Aaron and Rafi, Imran and Ray, Simon and Stinton, Vicky and Venetucci, Luigi and Pirmohamed, Munir},
  title = {CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  volume = {92},
  number = {2},
  pages = {329--347},
  doi = {10.1002/bcp.70370}
}
Kostenlos starten →